Expertise in
5
conditions

Donna E. Reece

610 University Avenue, 
Toronto, ON, CA 
Expertise in
5
conditions
610 University Avenue, 
Toronto, ON, CA 

Overview

Donna Reece practices practicing medicine in Toronto, Canada.

Ms. Reece is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Primary Amyloidosis, Agranulocytosis, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 149 peer reviewed articles and participating in 5 clinical trials.

Gender

Female

Locations

610 University Avenue, Toronto, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 12, 2026
Intervention Type: Drug
Study Drugs: Elotuzumab, Pomalidomide, Dexamethasone
Study Phase: Phase 2
The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study
The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2025
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma
A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 04, 2023
Intervention Type: Biological
Study Drugs: DCdP, DCd+P
Study Phase: Phase 2
A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects With Lymphoid Hematological Malignancies
A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects With Lymphoid Hematological Malignancies
Enrollment Status: Terminated
Publish Date: February 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 4 Less Clinical Trials

149 Total Publications

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
Journal: Lancet (London, England)
Published: April 29, 2026

Frequently Asked Questions about Donna E. Reece

Is Donna E. Reece a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Donna E. Reece is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Donna E. Reece participate in research or clinical trials?

Yes. Donna E. Reece has published 149 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Donna E. Reece's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Reece's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile